Endocyte, Inc. (NASDAQ: ECYT) today announced that following a meeting with the U.S. Food and Drug Administration (FDA), it was ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Endocyte (ECYT) Prices 9.5M Share Common Offering at $18.50/ShSeptember 12, 2018 5:47 AM Endocyte (ECYT) Announces Proposed $175M Common Share OfferingSeptember 10, 2018 4:17 PM Endocyte Announces FDA Acceptance of Radiographic Progression Free Survival (rPFS) as an Alternative Primary Endpoint of the VISION Trial in Addition to Overall Survival (OS)September 10, 2018 8:00 AM